Astellas Pharma (OTCMKTS:ALPMY) Hits New 12-Month Low at $9.15

Astellas Pharma Inc. (OTCMKTS:ALPMY) reached a new 52-week low during trading on Tuesday . The company traded as low as $9.15 and last traded at $9.34, with a volume of 692432 shares trading hands. The stock had previously closed at $9.27.

Astellas Pharma Stock Performance

The company’s fifty day moving average price is $10.73 and its two-hundred day moving average price is $11.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a market capitalization of $17.14 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.28 and a beta of 0.32.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.12 earnings per share for the quarter. The company had revenue of $2.86 billion for the quarter. Astellas Pharma had a net margin of 0.08% and a return on equity of 6.39%. As a group, equities analysts expect that Astellas Pharma Inc. will post 0.35 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.